Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

Cited In for PubMed (Select 12042700)

1.

NADPH Oxidase-generated Hydrogen Peroxide Induces DNA Damage in Mutant FLT3-expressing Leukemia Cells.

Stanicka J, Russell EG, Woolley JF, Cotter TG.

J Biol Chem. 2015 Apr 10;290(15):9348-61. doi: 10.1074/jbc.M113.510495. Epub 2015 Feb 19.

PMID:
25697362
2.

Preclinical antitumor activity of SST0116CL1: a novel heat shock protein 90 inhibitor.

Vesci L, Milazzo FM, Carollo V, Pace S, Giannini G.

Int J Oncol. 2014 Oct;45(4):1421-9. doi: 10.3892/ijo.2014.2575. Epub 2014 Aug 1.

3.

Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors.

Wichmann C, Quagliano-Lo Coco I, Yildiz Ö, Chen-Wichmann L, Weber H, Syzonenko T, Döring C, Brendel C, Ponnusamy K, Kinner A, Brandts C, Henschler R, Grez M.

Leukemia. 2015 Feb;29(2):279-89. doi: 10.1038/leu.2014.179. Epub 2014 Jun 4.

4.

Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants.

Chen X, Radany EH, Wong P, Ma S, Wu K, Wang B, Wong JY.

PLoS One. 2013 Dec 19;8(12):e84515. doi: 10.1371/journal.pone.0084515. eCollection 2013.

5.

Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.

Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1223-34. doi: 10.1007/s00280-013-2287-6. Epub 2013 Oct 2.

6.

Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies.

Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE.

Leuk Res. 2013 Nov;37(11):1461-7. doi: 10.1016/j.leukres.2013.07.034. Epub 2013 Aug 6.

7.

Abundance of Flt3 and its ligand in astrocytic tumors.

Eßbach C, Andrae N, Pachow D, Warnke JP, Wilisch-Neumann A, Kirches E, Mawrin C.

Onco Targets Ther. 2013 May 24;6:555-61. doi: 10.2147/OTT.S43114. Print 2013.

8.

Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML.

Borate U, Absher D, Erba HP, Pasche B.

Expert Rev Anticancer Ther. 2012 Oct;12(10):1289-97. doi: 10.1586/era.12.116.

9.

Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia.

Williams AB, Li L, Nguyen B, Brown P, Levis M, Small D.

Blood. 2012 Oct 11;120(15):3069-79. doi: 10.1182/blood-2012-01-403493. Epub 2012 Aug 27.

10.

Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers.

del Corral A, Dutreix C, Huntsman-Labed A, Lorenzo S, Morganroth J, Harrell R, Wang Y.

Cancer Chemother Pharmacol. 2012 May;69(5):1255-63. doi: 10.1007/s00280-012-1825-y.

11.

BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML.

Lin WH, Jiaang WT, Chen CW, Yen KJ, Hsieh SY, Yen SC, Chen CP, Chang KY, Chang CY, Chang TY, Huang YL, Yeh TK, Chao YS, Chen CT, Hsu JT.

Br J Cancer. 2012 Jan 31;106(3):475-81. doi: 10.1038/bjc.2011.564. Epub 2011 Dec 20.

12.

RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.

Lipkowitz S, Weissman AM.

Nat Rev Cancer. 2011 Aug 24;11(9):629-43. doi: 10.1038/nrc3120. Review.

13.
14.

Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication.

Rickmann M, Krauter J, Stamer K, Heuser M, Salguero G, Mischak-Weissinger E, Ganser A, Stripecke R.

Ann Hematol. 2011 Sep;90(9):1047-58. doi: 10.1007/s00277-011-1231-2. Epub 2011 Apr 26.

15.

The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway.

Hernandez-Davies JE, Zape JP, Landaw EM, Tan X, Presnell A, Griffith D, Heinrich MC, Glaser KB, Sakamoto KM.

Mol Cancer Ther. 2011 Jun;10(6):949-59. doi: 10.1158/1535-7163.MCT-10-0904. Epub 2011 Apr 6.

16.

Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy.

Fan J, Li L, Small D, Rassool F.

Blood. 2010 Dec 9;116(24):5298-305. doi: 10.1182/blood-2010-03-272591. Epub 2010 Aug 31.

17.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ.

J Clin Oncol. 2010 Oct 1;28(28):4339-45. doi: 10.1200/JCO.2010.28.9678. Epub 2010 Aug 23.

18.

Quantitative in situ detection of phosphoproteins in fixed tissues using quantum dot technology.

Bodo J, Durkin L, Hsi ED.

J Histochem Cytochem. 2009 Jul;57(7):701-8. doi: 10.1369/jhc.2009.953547. Epub 2009 Mar 30.

19.

Targeting FLT3 for the treatment of leukemia.

Small D.

Semin Hematol. 2008 Jul;45(3 Suppl 2):S17-21. doi: 10.1053/j.seminhematol.2008.07.007. Review.

20.

Epigenetics in acute myeloid leukemia.

Plass C, Oakes C, Blum W, Marcucci G.

Semin Oncol. 2008 Aug;35(4):378-87. doi: 10.1053/j.seminoncol.2008.04.008. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk